CD274 and renal cell carcinoma: Here, we provide a comprehensive review of studies on the PD-1 pathway in the kidneys, with a focus on renal cell carcinoma, glomerulonephritis, kidney transplantation, renal aging, and renal complication secondary to PD-1/PD-L1 inhibitor-related immunotherapy (Figure 3).